Our understanding of the mechanisms and specific components underlying the development and regression of liver fibrosis has matured toward clinical translation.
1 Specialized cell types such as activated hepatic stellate cells (HSCs) and myofibroblasts (MFs) 2, 3 are central effectors of fibrogenesis (see "Origin and Function of Myofibroblasts in the Liver" by Wells and Schwabe in this issue), and other cells such as liver macrophages can promote either fibrogenesis or fibrolysis in a context-dependent manner (see "Resolution of Liver Fibrosis: Basic Mechanisms and Clinical Relevance" by Ramachandran, Iredale, and Fallowfield in this issue). Moreover, the underlying etiology of chronic liver damage determines both the mechanism and pattern of liver fibrosis, likely necessitating different approaches to antifibrotic therapy (see below).
Instead of mere quantification of collagen and considering fibrosis as an endpoint, the dynamic processes of fibrogenesis and fibrolysis-the de novo formation and removal of connective tissue, respectively, that capture the dynamic nature of even advanced fibrosis-have taken center stage. Tissue injury is the most common stimulus for fibrogenesis, and immediately results in multiple coordinated processes aimed at initiating repair and regeneration, and at activating host defense. 4 
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Significant progress has been made in understanding the principles underlying the development of liver fibrosis. This includes appreciating its dynamic nature, the importance of active fibrolysis in fibrosis regression, and the plasticity of cell populations endowing them with fibrogenic or fibrolytic properties. This is complemented by an increasing array of therapeutic targets with known roles in the progression or regression of fibrosis. With a key role for fibrosis in determining clinical outcomes and encouraging data from recently Food and Drug Administration-approved antifibrotics for pulmonary fibrosis, the development and validation of antifibrotic therapies has taken center stage in translational hepatology. In addition to summarizing the recent progress in antifibrotic therapies, the authors discuss some of the challenges ahead, such as achieving a better understanding of the interindividual heterogeneity of the fibrotic response, how to match interventions with the ideal patient population, and the development of better noninvasive methods to assess the dynamics of fibrogenesis and fibrolysis. Together, these advances will permit a better targeting and dose titration of individualized therapies. Finally, the authors discuss combination therapy with different antifibrotics as possibly the most potent approach for treating fibrosis in the liver.
repair, regeneration, and activation of host defense. With time, cells, cytokine responses, and matrix components become more specialized, but continue to have potent interactions with each other. Inflammation can either enhance the fibrogenic signal, for example, via secretion of soluble mediators (interleukin [IL] 1-β, IL-13, IL-17, and PDGF-BB), or induce fibrolysis (interferon-[IFN-] γ or IL-12). On the other hand, chronic inflammation is often regulated and dominated by the immunosuppressive TGF-β1, which is a highly potent fibrogenic factor. These interactions make inflammatory responses an attractive target, and focused anti-inflammatory approaches are expected to reduce tissue injury and fibrogenesis, without compromising liver regeneration, which is particularly attractive in inflammatory pathologies such as alcoholic and nonalcoholic hepatitis.
The differences between individuals that determine why some repair with a scar-free liver while others proceed to cirrhosis are determined by genetic and environmental factors ("second hits"), and the quantity of these different contributing factors appear to determine the outcome. Thus, the contribution of each cellular or signaling pathway may vary between groups of individuals. However, from a therapeutic perspective the situation seems manageable because the pathways that lead to fibrogenesis or induce fibrolysis are common between individuals, and only differ quantitatively. It also stresses the necessity of a personalized approach to treatment of fibrosis, using, for example, several biomarkers that quantify key fibrogenic or fibrolytic pathways. Notably, most of the pathways found for the liver are also central pathways in the development or regression of fibrosis in other organs and vice versa.
1,5
It is important to recognize that fibrolysis is as complex and dynamic a process as fibrogenesis and provides additional therapeutic targets. Furthermore, cellular plasticity with economy of cellular populations is a common organizing principle. This is best demonstrated for liver macrophages that are key to the development of fibrogenesis as well as fibrolysis (see review by Ramachandran et al in this issue). This makes therapies that aim to delete cell populations deemed to be fibrogenic a blunt approach, which is likely to also limit fibrolysis.
Recognition of the full spectrum of changes associated with severe liver fibrosis is vital. In addition to quantitative and qualitative changes of the extracellular matrix (ECM), including increased ECM crosslinking and stiffness, liver fibrosis is associated with loss of hepatocytes, vascular remodeling, changes in cellular populations, and overall architectural distortion. The regenerative capacity of the liver is a great asset to all therapeutic strategies. However, therapies that aim to simply remove the ECM may not be effective against all the other pathological changes, and could even further impair liver function or increase the risk of liver cancer.
Principles of Antifibrotic Therapies
The recognition of heterogeneity in many aspects of fibrosis is a necessary step in therapeutic development. The fibrogenic pathways that are activated, and the relative amplitude of the inflammatory and fibrogenic responses vary significantly depending on the insult and its primary target cell, as exemplified by Schistosoma eggs (myeloid cells, lymphocytes), nonalcoholic steatohepatitis (NASH; hepatocytes, macrophages), or biliary obstruction (cholangiocytes). Inhibition of a single pathway upstream of the fibrogenic effector cells (HSCs and MFs) will likely generate a very different response in each of these conditions. Similarly, differences between early and advanced fibrosis will be extensive, as will be therapeutic responses. Further heterogeneity is present in the variable degree of fibrosis within the same liver. The very limited liver sampling possible by biopsy has entirely missed the variation that is present, and is now being revealed by noninvasive testing including elastography.
In view of this heterogeneity and the recent success of antiviral therapy, combination therapy for fibrosis is very attractive. 6 The simplest approach in combination therapy is to target two vital but very different pathways to reduce upstream (chronic) inflammation and downstream ECM deposition. Combination therapy is also necessary because rapid, homogeneous, and monocausal fibrosis development in animal experimental data typically reveal single targets as being central to fibrogenesis, whereas modulation of such single molecules or pathways does not prove to be highly efficient in man. From the perspective of clinical drug development, the demonstration of antifibrotic efficacy in one organ makes the agent a candidate as an antifibrotic in other organs, and also a candidate for a second drug to be added as combination therapy.
Preclinical Testing
In Vitro and In Vivo Models
In vitro models are necessary for early drug discovery to advance our understanding of the molecular pathogenesis of liver fibrosis, and for high throughput testing once a target has been identified. 7 These include culture-activated HSCs and HSC lines as well as other liver cells that are contributory to the fibrogenic or fibrolytic process. However, advanced preclinical proof of efficacy requires selected animal models, preferably mouse models that permit assessment of antifibrotic efficacy in the complex multicellular context and provide information on bioavailability, pharmacokinetics, pharmacodynamics, and toxicity. Because these models are only an approximation to the human scenario, there has been a tendency to omit a thorough in vivo preclinical validation before initiating larger phase 2 clinical studies. Examples are the 2-year studies of interferon-γ and the highly potent peroxisome proliferator activated receptor-γ (PPARγ) agonist Farglitazar in patients with advanced-stage hepatitis C, which yielded no effect by state-of-the-art biopsy-based fibrosis readouts.
8,9
Animal models should reproduce the varied features of human liver fibrosis. These features include the degree and pattern of inflammation, biliary versus parenchymal damage, time course, and reversibility. Incorporation of the causative agent-hepatotropic virus, alcohol, or metabolic syndrome-is ideal, but can only be achieved for some disease or using humanized mice.
10 Although no single model will perfectly represent even a given human etiology, useful predictions as to antifibrotic efficacy appear to be possible by using combinations. Thus, mice that lack the hepatocyte phospholipid flippase Mdr2 provide a model of spontaneous biliary fibrosis progression resembling primary sclerosing cholangitis, and discontinuation of toxin-administration in advanced toxininduced fibrosis mimics advanced human parenchymal fibrosis with little tendency to reverse. 11, 12 Both models are characterized by only low-level inflammation and therefore show similarities to the target patients with advanced fibrosis of low-to-moderate inflammatory activity. Drugs that work in both models (inhibiting progression and inducing regression, respectively) may have a relatively high probability to be effective in man.
There has been significant progress in the development of rodent models of NASH. Earlier models produced components of NASH including steatosis and inflammation.
13,14
Recently, diet-based models that use high-fat diets supplemented with cholesterol and fructose have captured central features of NASH including the metabolic syndrome, steatosis, inflammation, and fibrosis. 15 An additional limitation is that the vast majority of studies are performed in a single strain of mice (typically C57BL/6), yet there are significant differences in fibrosis susceptibility between strains. Experiments are also typically done with young (6-12-week-old) mice, whereas liver fibrosis is usually a disease of older age, with older age as a risk factor for faster fibrosis progression.
Transgenic and Gene Deletion Models
Genetic models can confirm factors and mechanisms that drive fibrogenesis or fibrolysis in vivo, for example, transgenic mice with overexpression of PDGF-B, PDGF-C, or TGFβ1.
16-18
However, these models do not reflect the multifaceted nature of human liver fibrosis, and lack chronic inflammatory liver injury, a key component in the development of fibrosis and long-term complications. 19 Finally, in vivo models have to be done in an optimal and standardized quality, coupled with fibrosis readouts that accord to state of the art. This includes (1) group sizes of > 10 animals, (2) analysis of samples of sufficient size (5%-10% of the liver), and (3) use of complementary quantitative fibrosis and fibrolysis readouts. Notably, several past studies do not satisfy these criteria. 
Precision-Cut Tissue Slices
A criticism of animal studies is their unclear transferability to the humans, which may vary with the pharmacological target. Human precision-cut tissue slices (PCTS) that can be cultured for several days are $200-µm-thick punches of liver that partly reflect the multicellular human context.
20,21
Precision-cut tissue slices can be obtained either from normal livers (resections, spontaneous fibrogenic activation ex vivo) or from cirrhotic explants. Multiple drugs can be tested in slices prepared from a small tissue block. This technology may serve as a preclinical bridge between animal models and the patient setting. However, more studies are needed for its validation.
One major obstacle is the species difference, with significant biological differences between rodents and humans. 22 An approach to identify pathways that are important for fibrosis in humans is the concept of core pathways that are required for fibrosis in multiple organs and species. 23 Increased testing of pathways in multiple organs in rodents is relatively straightforward, and able to provide a greater degree of certainty that the pathway will be important across different species. A second important issue is the high degree of homogeneity in experimental models. The test and control populations in experimental models are homogeneous across a wide range of parameters, including, age, sex, genetic background, diet, microbiome, etc. None of these will apply to the eventual human population, and it is relevant to ask if the efficacy of a compound as an antifibrotic is maintained if there is a controlled break in homogeneity in experimental models.
The Immune Response as an Antifibrotic Target
The immune response interacts with fibrogenesis and fibrolysis at multiple points, and is an attractive candidate for therapy. 24 The healthy liver is notable for a very vigorous innate and subdued adaptive immune response. Targeting some of these molecules promises to be an effective antifibrotic strategy. To take TGF-β1 as an example, several strategies to block its activity have demonstrated efficacy in rodent models of liver fibrosis. These strategies include a fully humanized anti-TGF-β1 antibody (Lerdelimumab), soluble TGF-β1 receptors, blocking peptides, and a small molecule to block downstream activin receptor-like kinase activity (SB431542; NCT 00125385, 01665391, 01262001). shared concern is that these mediators affect different cell types and are involved in many processes including angiogenesis, and cellular proliferation and differentiation; their inhibition may have significant off-target effects as well.
been vital for fibrogenesis undergo a major phenotypic switch, with enhanced production of e.g., matrix metalloproteinases (MMPs) to degrade the excess ECM and the release of proapoptotic ligands such as TRAIL, which can induce HSC and MF apoptosis. 
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All antifibrotic therapies, particularly those that exert a regulatory activity, need to consider that the liver is never affected by fibrosis alone, but also by the underlying (usually inflammatory) disease. In this respect, fibrosis needs to be addressed in the context of the original disease. Antifibrotic therapies will affect many pathways. To increase efficacy and reduce side effects, therapies for specific fibrotic diseases will have to be well selected.
Regulating Platelet and Endothelial Function
Hepatic stellate cells are positioned adjacent to liver sinusoidal endothelial cells (LSECs), and the two have close functional interactions. 57 After liver injury and the initiation of fibrosis are a loss of fenestrations in LSECs, increased expression of vasoconstrictors (ET-1 and angiotensin II), and decreased activity of vasodilators, most prominently nitric oxide (NO). 58 In addition to these classic vascular changes, LSECs contribute to deposition of ECM (e.g., fibronectin and collagens I and IV), and cytokine production (e.g., TGF-β1 and PDGF-BB). 59 Liver sinusoidal endothelial cells can also respond to changes in sinusoidal shear stress, with enhanced production of NO.
60-62
Therapeutic targeting of LSECs in fibrosis has focused on their predominant role in regulating the dynamic part of intrahepatic portal hypertension, which is a major cause of Antifibrotic Therapies in the Liver Mehal, Schuppan 187 morbidity and mortality in cirrhosis. Interventions have included broad spectrum kinase inhibitors such as sorafenib or sunitinib, and inhibitors of vascular endothelial growth factor and endothelial growth factor. Such interventions have resulted in changes that go beyond the hemodynamic to include reduction of fibrotic matrix. 63, 64 It is unclear how much of this reduction in fibrosis is due to regulation by LSECs, and how much of it is due to non-LSEC actions of these agents. However, as in inflammation, angiogenic mediators, while being profibrogenic during progression, can promote fibrolysis during regression. 65 Liver sinusoidal endothelial cells also have a key role in regulating the relative response between liver regeneration and fibrosis. This is due to a stromal factor derived pathway, which can activate the chemokine receptors CXCR7 and CXCR4. 66 After acute injury, activation of the CXCR7 pathway with recruitment of the downstream transcription factor Id1 results in a regenerative response. Chronic injury, however, results in a persistent activation of the FGF receptor 1 in LSEC that dampens the CXCR7-Id1 pathway, and activates a CXCR4 driven profibrotic pathway. Such pathways that regulate the switch between regeneration and fibrosis are excellent candidates for therapeutic intervention.
67
Platelets are a rich source of profibrogenic factors, such as PDGF-BB and TGF-β1, but the role of platelets in fibrogenesis had been understudied. 
The ECM and Integrins as Antifibrotic Targets
A change in the composition and an increase in the amount of the ECM is the defining feature of all forms of fibrosis. In the normal liver, the extracellular matrix is composed predominantly of macromolecules including collagens (mainly the interstitial types I, III, V, VI, and the basement membrane types IV, XV, XVIII, and XIX), and a range of glycoproteins such as laminin isoforms and fibronectin, and several proteoglycans. [70] [71] [72] During the development of rodent and human cirrhosis, there is a 5-to10-fold increase in the content of collagens, particularly of fibril-forming types I and III, and an increase of elastin, laminins, and proteoglycans, 73 which is accompanied by more highly crosslinked collagen fibers. The total amount of ECM is not only dependent on the rate of production, but also largely on the balance between the matrix degrading MMPs, and the inhibitors of metalloproteinases (TIMPs), especially TIMP-1. Therefore, the relative cellular specificity of the αv and especially TGF-β1 activating integrin αvβ6 permits selective inhibition of TGF-β activity in areas of mechanical stiffness and associated fibrogenesis. This is vital as total inhibition is known to result in unwanted proinflammatory changes. 90 More generally, the family of αv integrins is expressed on many liver cell populations; genetic deletion or pharmacological inhibition of all αv integrins results in attenuated fibrogenesis, 91 or in the abundant integrin αvβ3 (and αvβ5) that is mainly expressed on HSCs/ MF and macrophages.
92,93
Collagens, the major ECM proteins in fibrosis, and elastin are stabilized via enzymatic crosslinking, which confers resistance to degradation, and thus may limit reversibility of established fibrosis. 94 There has been a focus on the family of lysyl oxidases (LOX) that crosslink fibrillary collagen mainly at the nontriple helical ends (telopeptides) of the collagen molecules. 11,95 LOX enzymes constitute a family of five members: LOX and LOX-like (LOXL) 1-4. They are secreted, copper-dependent amine oxidases with a variable N-terminal region and a conserved C-terminal domain that is necessary for catalytic activity. Expression of the LOX proteins is tightly controlled in a time-and organ-dependent manner during development, but aberrant expression and activity of these enzymes has been reported in a range of diseases associated with the ECM and in cancers, 96, 97 
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Attenuating the activated phenotype of myofibroblasts is an attractive approach due to their key role in ECM Antifibrotic Therapies in the Liver Mehal, Schuppan 191
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. deposition. Inhibition of the cannabinoid receptor 1 (CB1) reverses myofibroblast activation and attenuates experimental liver fibrosis. 109 This has passed the proof of principle state, and peripheral-acting CB1 antagonists that may circumvent adverse side effects on the central nervous system like depression are being developed. 110 In fibrotic NASH, progression is intimately linked to insulin resistance/type 2 diabetes, and the associated lipotoxic hepatocyte death and intestinal dysbiosis, providing rational targets for both antiinflammatory and antifibrotic therapy in this condition.
111,112
Therapeutic strategies include reducing oxidative stress, improving insulin signaling, activating the farnesoid X receptor receptor (e.g., with obeticholic acid), fibrosis-targeted inhibitors of hedgehog signaling, combined peroxisome proliferator activated receptor (PPAR)α/δ agonists, [113] [114] [115] or manipulation of the altered gut microbiota using probiotics or microbiota transfer.
112,116
Oxidative stress is an important cofactor in fibrosis, but the use of antioxidants has been disappointing. 117 This may be due to differences between animal models and human disease, and the fibrosis stage and cell-specific regulation of oxidant and antioxidant pathways. Activation of NADPH oxidases (NOX1, NOX 2, and NOX4) induces HSC activation 118-120 NOX4 can trigger apoptosis in hepatocytes.
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Inhibition of NOX1/NOX4 suppresses fibrogenesis in the CCl 4 and bile duct ligation models, in pulmonary 120-122 and in interstitial kidney fibrosis. A phase II trial is underway in diabetic kidney disease (ClinicalTrials.gov NCT02010242). ►Tables 1 and 2 list relevant clinical drug trials using antifibrotic agents in liver fibrosis or other organ fibrosis with fibrosis as the primary or coprimary endpoint. What is remarkable is the diversity of agents that have been tested. They range from drugs with very broad or poorly characterized mechanism (e.g., omega-3 fats and vitamin D), to specific receptor inhibitors (losartan and liraglutide), broad but fairly low intensity anti-inflammatory and antiapoptotic effects (pentoxifylline and ursodeoxycholic acid), or multikinase inhibitors (nintedanib). This is a reflection of the wide range of biological processes that are involved in the development of liver fibrosis. Due to the obvious concerns of redundant pathways, and individual heterogeneity in active pathways that lead to fibrosis, there is a significant risk that many of the single agents listed may not have significant efficacy and/or display off-target side effects. However, the past and current studies are already providing a rich resource for designing effective treatments that would also exploit drug combinations in the near future. Notably, two antifibrotics (pirfenidone and nintedanib) have recently been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary fibrosis.
The Patient Population to Be Studied
Recent reviews and guidelines highlight optimal patient selection and stratification for proof-of-concept clinical trials. 
Combination Therapies
Considering the expected synergies of modulating two or more fibrogenic (and/or fibrolytic) pathways and the potential to decrease or eliminate the side effects that may result from targeting a single mechanism, combinations of antifibrotic (anti-inflammatory) therapies hold great promise. Agents in such combinations can address the major cause of fibrosis, such as antivirals; derive from drugs with known safety profiles that are used for other cardiovascular or inflammatory indications in a process of drug repurposing; or be specifically targeted at fibrogenic or fibrolytic cells and pathways. Such drug combinations would factor in the multifactorial etiology of fibrosis and the quantitatively divergent fibrogenic pathways in each individual, which would likely also reduce potential side effects. However, despite its promise at present there is only scant data on the efficacy of combinations of potential antifibrotic agents due to the effort needed even at the preclinical stage. 1 In man, clinical development of combination therapies that could guarantee thorough efficiency and low toxicity will only be possible with noninvasive tools that measure the effect of a given drug on its pharmacological target. In addition, we will need improved noninvasive biomarkers for the quantification of liver fibrosis, fibrogenesis, and liver function: surrogate markers for a personalized antifibrotic treatment that would permit titering of the given drugs and their combinations according to the individual antifibrotic response. The development and validation of such biomarkers has become a key focus of pharmaceutical and biotechnology companies with an interest in antifibrotic therapies. 
